vinorelbine nvb sold brand name navelbine among others chemotherapy medication used treat number types includes breast cancer nonsmall cell lung given injection vein common side effects include bone marrow suppression pain site injection vomiting feeling tired numbness serious side effects include shortness use pregnancy may harm vinorelbine vinca alkaloid family believed work disrupting normal function microtubules thereby stopping cell vinorelbine approved medical use united states world health organizations list essential vinorelbine approved treatment nonsmallcell lung used offlabel cancers metastatic breast cancer also active vinorelbine number sideeffects limit use chemotherapyinduced peripheral neuropathy progressive enduring often irreversible tingling numbness intense pain hypersensitivity cold beginning hands feet sometimes involving arms lowered resistance infection bruising bleeding anaemia constipation vomitings diarrhea nausea tiredness general feeling weakness asthenia inflammation vein injected phlebitis seldom severe hyponatremia seen less common effects hair loss allergic reaction antitumor activity due inhibition mitosis interaction vinorelbine invented pharmacist pierre potier team cnrs france licensed oncology department pierre fabre group drug approved france brand name navelbine treatment nonsmall cell lung cancer gained approval treat metastatic breast cancer vinorelbine received approval united states food drug administration fda december sponsored burroughs wellcome company pierre fabre group markets navelbine us drug went generic february european countries vinorelbine approved treat nonsmall cell lung cancer breast cancer united states approved nonsmall cell lung cancer madagascan periwinkle catharanthus roseus l source number important natural products including catharanthine vinca alkaloids produces leurosine chemotherapy agents vinblastine vincristine obtained newer semisynthetic chemotherapeutic agent vinorelbine used treatment nonsmallcell lung known occur naturally however prepared either vindoline cases synthesis anhydrovinblastine leurosine pathway uses reagent highly chemoselective deoxygenation anhydrovinblastine reacted sequentially nbromosuccinimide trifluoroacetic acid followed silver tetrafluoroborate yield oral formulation marketed registered european countries similar efficacy intravenous formulation avoids venous toxicities infusion easier takemedical citation needed oral form approved united states australiamedical citation needed httpsenwikipediaorgwikivinorelbine